search
Back to results

The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans

Primary Purpose

Insulin Resistance, Atherosclerosis

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Cranberry Extract
Placebo
Sponsored by
Pennington Biomedical Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Insulin Resistance focused on measuring Cranberry Extract

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Are 20 years of age or older
  • Not being treated with diabetes medication. However, if you are taking Metformin for pre-diabetes and are willing to stop taking the medication 2 weeks before and during the study that is ok. We will request clearance from your prescribing physician prior to stopping metformin and enrolling in the study.
  • Have a blood sugar of 100-125 mg/dL (fasting) or 140-199 mg/dL after a 2 hour glucose tolerance test (determined by tests done at the screening visit)
  • Have a fasting insulin more than or equal to 5 µIU/ml (determined by tests done at the screening visit)
  • Have a Body Mass Index (BMI) ≥ 30 and ≤ 45.

Exclusion Criteria:

  • Have a prior history of type 2 diabetes
  • Are pregnant or breastfeeding.
  • Are a woman able to have children and are not using birth control (i.e. barrier method, intrauterine and cervical devices, birth control pills, hormonal injections (Depo Provera® ), condoms with spermicidal gel or foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence), or have had a tubal ligation or hysterectomy, or not at least 2 years past menopause.

    - All women able to have children will have a pregnancy test at the screening visit. If you become pregnant during the study, you will be dropped from the study.

  • Have type 1 diabetes.
  • Are taking steroids (except topical or inhaled steroids).

    - Other medications that may affect your blood sugar (i.e. certain blood pressure medications) are acceptable if the dose has not changed in the previous 6 months and the dose will not change during the study.

  • Have a history or evidence of stomach or intestinal problems, e.g. irritable bowel syndrome; inflammatory bowel disease; ulcerative colitis or Crohn's disease; diverticulosis or diverticulitis; narrowing of the intestines, partial or complete removal of the stomach or small bowel; autonomic neuropathy consisting of difficulty swallowing; delayed stomach emptying or diarrhea; chronic, severe constipation; stomach or colon ulcers, or GI bleeding.
  • Use laxatives or cathartics on a chronic basis.
  • Take medications known to damage the kidneys, such as certain antibiotics, methicillin, and cyclosporin.
  • Have any evidence of kidney disease.
  • Have significant heart problems and/or history (within the last 6 months) of significant heart problems.
  • Have evidence within the previous 6 months of liver disease such as hepatitis; jaundice; cirrhosis.
  • Have clinically significant lung, neurologic, blood-related, immune system-related, cancer-related or metabolic disease.
  • Have had a recurrence of cancer within the past five years, other than treated basal cell carcinoma.
  • Are planning surgery during the study period.
  • Have a history of substance abuse or alcoholism within the past 5 years, or significant psychiatric disorder that would interfere with your ability to complete the study.
  • Have donated blood during the month before entering the study or are planning to donate blood during the study.
  • Have participated in other studies using a research medication during the previous 3 months.
  • Are currently smoking or have smoked within the past 6 months.

    - No smoking will be allowed during the study.

  • Have had a fluctuation in body weight >5% in the previous 2 months.
  • Are taking prescription or over-the-counter medication for weight loss.
  • Are taking weight loss or herbal supplements.
  • Are taking prescription or over-the-counter anti-inflammatory medications (such as naproxen, aspirin, ibuprofen).
  • Are allergic to cranberries

Sites / Locations

  • Pennington Biomedical Research Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Cranberry Extract

Placebo

Arm Description

Cranberry Extract in a 15.2oz beverage daily for 8 weeks

Placebo 15.2oz beverage daily for 8 weeks

Outcomes

Primary Outcome Measures

Change from baseline Hyperinsulinemic-Euglycemic clamp at week 8
Insulin sensitivity is tested using a 120 mU/m2 hyperinsulinemic-euglycemic clamp at 100mg/dL glucose over 2 hours at weeks 0 and 8

Secondary Outcome Measures

Change from baseline in endothelial function at week 7
Endothelial function by peripheral arterial tone (PAT) with an endo-PAT device prior to week 0 and week 7 as a surrogate measure of atherosclerosis.
Change from baseline in Indirect Calorimetry at week 8
Resting metabolic rate via indirect calorimetry will be measured using a Deltatrac II Metabolic cart at week 0 and week 8 as part of the hyperinsulinemic euglycemic clamp.
Change from screening to week 8 in lipid profile
A comprehensive metabolic profile (CHEM 15) will be obtained at screening and then at week 8.
Change in body weight from baseline to week 8
Body weight will be assessed at baseline and week 8.
Change from screening to week 7 in oral glucose tolerance test (OGTT)
A 2 hr OGTT will be performed prior to week 0 and at week 7
Change in nitric oxide level at baseline and week 8
Levels of nitric oxide will be assessed at baseline and after 8 weeks of intervention
Change in endothelin 1 level at baseline and week 8
Levels of endothelin 1 will be assessed at baseline and after 8 weeks of intervention
Change in oxidized LDL level at baseline and week 8
Levels of oxidized LDL will be assessed at baseline and after 8 weeks of intervention
Change in LOX-1 (Lectin-like oxidized low density lipoprotein-1) at baseline and week 8
Levels of LOX-1 (Lectin-like oxidized low density lipoprotein-1) will be assessed at baseline and after 8 weeks of intervention
Change in 8-isoprostanes at baseline and week 8
Levels of 8-isoprostanes will be assessed at baseline and after 8 weeks of intervention
Change in malondialdehyde at baseline and week 8
Levels of malondialdehyde will be assessed at baseline and after 8 weeks of intervention
Change in advanced glycation end products at baseline and week 8
Levels of advanced glycation end products will be assessed at baseline and after 8 weeks of intervention
Change in Apo A1 at baseline and week 8
Levels of Apo A1 will be assessed at baseline and after 8 weeks of intervention
Change in Paraoxonase at baseline and week 8
Levels of Paraoxonase will be assessed at baseline and after 8 weeks of intervention
Change in Adiponectin at baseline and week 8
Levels of Adiponectin will be assessed at baseline and after 8 weeks of intervention
Change in C-reactive protein (CRP) at baseline and week 8
Levels of C-reactive protein (CRP) will be assessed at baseline and after 8 weeks of intervention
Change in TNFα at baseline and week 8
Levels of TNFα will be assessed at baseline and after 8 weeks of intervention

Full Information

First Posted
February 18, 2014
Last Updated
August 27, 2018
Sponsor
Pennington Biomedical Research Center
Collaborators
Ocean Spray, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02068144
Brief Title
The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans
Official Title
The Effect of Daily Dietary Supplementation With Cranberry Extract on Modulation of Cardiovascular Risk Factors in Obese, Insulin Resistant Human Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
June 2, 2016 (Actual)
Study Completion Date
July 11, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pennington Biomedical Research Center
Collaborators
Ocean Spray, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the health benefits of cranberry extract in people who are at risk for diabetes and heart problems.
Detailed Description
This study will be a double-blinded, randomized, placebo-controlled, pilot study in which subjects with pre-diabetes will be randomized to receive either placebo or Cranberry extract for a total of 8 weeks of treatment. Each subject will continue on the same dosage of cranberry extract or matching placebo for the entire duration of treatment. Comparisons for insulin sensitivity, endothelial function, and markers of inflmmation and oxidative stress will be made between the 2 groups pre and post intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Resistance, Atherosclerosis
Keywords
Cranberry Extract

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
35 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cranberry Extract
Arm Type
Experimental
Arm Description
Cranberry Extract in a 15.2oz beverage daily for 8 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo 15.2oz beverage daily for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Cranberry Extract
Intervention Description
Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
Primary Outcome Measure Information:
Title
Change from baseline Hyperinsulinemic-Euglycemic clamp at week 8
Description
Insulin sensitivity is tested using a 120 mU/m2 hyperinsulinemic-euglycemic clamp at 100mg/dL glucose over 2 hours at weeks 0 and 8
Time Frame
8 weeks +/- 2 days
Secondary Outcome Measure Information:
Title
Change from baseline in endothelial function at week 7
Description
Endothelial function by peripheral arterial tone (PAT) with an endo-PAT device prior to week 0 and week 7 as a surrogate measure of atherosclerosis.
Time Frame
8 weeks +/- 2 days
Title
Change from baseline in Indirect Calorimetry at week 8
Description
Resting metabolic rate via indirect calorimetry will be measured using a Deltatrac II Metabolic cart at week 0 and week 8 as part of the hyperinsulinemic euglycemic clamp.
Time Frame
8 weeks +/- 2 days
Title
Change from screening to week 8 in lipid profile
Description
A comprehensive metabolic profile (CHEM 15) will be obtained at screening and then at week 8.
Time Frame
10 weeks +/- 2 days
Title
Change in body weight from baseline to week 8
Description
Body weight will be assessed at baseline and week 8.
Time Frame
8 weeks +/- 2 days
Title
Change from screening to week 7 in oral glucose tolerance test (OGTT)
Description
A 2 hr OGTT will be performed prior to week 0 and at week 7
Time Frame
8 weeks +/- 2 days
Title
Change in nitric oxide level at baseline and week 8
Description
Levels of nitric oxide will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in endothelin 1 level at baseline and week 8
Description
Levels of endothelin 1 will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in oxidized LDL level at baseline and week 8
Description
Levels of oxidized LDL will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in LOX-1 (Lectin-like oxidized low density lipoprotein-1) at baseline and week 8
Description
Levels of LOX-1 (Lectin-like oxidized low density lipoprotein-1) will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in 8-isoprostanes at baseline and week 8
Description
Levels of 8-isoprostanes will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in malondialdehyde at baseline and week 8
Description
Levels of malondialdehyde will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in advanced glycation end products at baseline and week 8
Description
Levels of advanced glycation end products will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in Apo A1 at baseline and week 8
Description
Levels of Apo A1 will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in Paraoxonase at baseline and week 8
Description
Levels of Paraoxonase will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in Adiponectin at baseline and week 8
Description
Levels of Adiponectin will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in C-reactive protein (CRP) at baseline and week 8
Description
Levels of C-reactive protein (CRP) will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days
Title
Change in TNFα at baseline and week 8
Description
Levels of TNFα will be assessed at baseline and after 8 weeks of intervention
Time Frame
8 weeks +/- 2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Are 20 years of age or older Not being treated with diabetes medication. However, if you are taking Metformin for pre-diabetes and are willing to stop taking the medication 2 weeks before and during the study that is ok. We will request clearance from your prescribing physician prior to stopping metformin and enrolling in the study. Have a blood sugar of 100-125 mg/dL (fasting) or 140-199 mg/dL after a 2 hour glucose tolerance test (determined by tests done at the screening visit) Have a fasting insulin more than or equal to 5 µIU/ml (determined by tests done at the screening visit) Have a Body Mass Index (BMI) ≥ 30 and ≤ 45. Exclusion Criteria: Have a prior history of type 2 diabetes Are pregnant or breastfeeding. Are a woman able to have children and are not using birth control (i.e. barrier method, intrauterine and cervical devices, birth control pills, hormonal injections (Depo Provera® ), condoms with spermicidal gel or foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence), or have had a tubal ligation or hysterectomy, or not at least 2 years past menopause. - All women able to have children will have a pregnancy test at the screening visit. If you become pregnant during the study, you will be dropped from the study. Have type 1 diabetes. Are taking steroids (except topical or inhaled steroids). - Other medications that may affect your blood sugar (i.e. certain blood pressure medications) are acceptable if the dose has not changed in the previous 6 months and the dose will not change during the study. Have a history or evidence of stomach or intestinal problems, e.g. irritable bowel syndrome; inflammatory bowel disease; ulcerative colitis or Crohn's disease; diverticulosis or diverticulitis; narrowing of the intestines, partial or complete removal of the stomach or small bowel; autonomic neuropathy consisting of difficulty swallowing; delayed stomach emptying or diarrhea; chronic, severe constipation; stomach or colon ulcers, or GI bleeding. Use laxatives or cathartics on a chronic basis. Take medications known to damage the kidneys, such as certain antibiotics, methicillin, and cyclosporin. Have any evidence of kidney disease. Have significant heart problems and/or history (within the last 6 months) of significant heart problems. Have evidence within the previous 6 months of liver disease such as hepatitis; jaundice; cirrhosis. Have clinically significant lung, neurologic, blood-related, immune system-related, cancer-related or metabolic disease. Have had a recurrence of cancer within the past five years, other than treated basal cell carcinoma. Are planning surgery during the study period. Have a history of substance abuse or alcoholism within the past 5 years, or significant psychiatric disorder that would interfere with your ability to complete the study. Have donated blood during the month before entering the study or are planning to donate blood during the study. Have participated in other studies using a research medication during the previous 3 months. Are currently smoking or have smoked within the past 6 months. - No smoking will be allowed during the study. Have had a fluctuation in body weight >5% in the previous 2 months. Are taking prescription or over-the-counter medication for weight loss. Are taking weight loss or herbal supplements. Are taking prescription or over-the-counter anti-inflammatory medications (such as naproxen, aspirin, ibuprofen). Are allergic to cranberries
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel Hsia, MD
Organizational Affiliation
Principal and Medical Investigator
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pennington Biomedical Research Center
City
Baton Rouge
State/Province
Louisiana
ZIP/Postal Code
70808
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans

We'll reach out to this number within 24 hrs